Pascal COLOSETTI

14
Documents

Présentation

Professional experience

53 publications (December 15th, 2020)

2848 citations

H-Index: 23

2016-Today Research engineer within Inserm U1060-INRAe 1397-CarMeN (H. Vidal, Lyon, France): expertise in studying extracellular vesicles from different origins (eukaryotes and plants)

Director of the European School for the Study of Extracellular Vesicles (ESSEV, @EV_School_ESSEV)

2012-2017 Member of the Inserm Scientific Council

2001-2016 Research engineer within Inserm U1065-C3M (P. Auberger, Nice, France): Extracellular vesicles (microvesicles and exosomes) in cancer, chemoresistance and inflammation

1997-2001 Research engineer within Inserm U442 (J.-P. Mauger, Orsay, France): InsP3R expression and regulation during cell polarization

Diplomas and qualifications

2011 International Cancer Technology Transfer fellow at the Krefting Research Centre-Göteborg University, (Prof. J. Lötvall, Sweden) (UICC-ICRETT grant)

2008 Inter-university diploma (DIU) on acquired chromosomal pathologies (Bordeaux, Grenoble, Lille, Lyon, Marseille, Nice and Paris-Sud Universities)

2000 Transgenesis and homologous recombination diploma (Paris 6 University)

1994-1997 Postdoctoral fellow at the Laboratoire de Recherche en Oncologie of the Centre Alexis Vautrin (Nancy, France): Anticancer treatment resistance (Prof. J.-L. Merlin)

1991-1994 Postdoctoral fellow at the Ludwig Institute for Cancer Research (Uppsala, Sweden): TGF-beta activation and LTBP expression (Prof. C.-H. Heldin and Prof. K. Miyazono)

1991-1987 PhD in Biomedical Engineering at the Inserm U284 (Nancy University, France): TGF-beta 1 purification, a human platelet derived growth factor (C. Rivat and Prof. J.F. Stoltz)

After completing my PhD on the TGF-beta 1 purification, a human platelet derived growth factor, at the Inserm U284 in Nancy, I was as a postdoctoral fellow at the Ludwig Institute for Cancer Research in Uppsala on TGF-beta activation and LTBP expression; followed by an other fellowship at the Laboratoire de Recherche en Oncologie (Centre Alexis Vautrin in Nancy) coordinating a cancer treatment resistance project.

I then got a permanent position as research engineer at the Inserm U442 in Orsay to study the InsP3R expression during cell polarization.

I next joined the Inserm U1065-C3M in Nice involved in cell death, differentiation, inflammation and cancer; last years, I developed skills in the characterization of extracellular vesicles (microvesicles, exosomes...) in cancer, chemoresistance and inflammation.

I'm now part of the Inserm U1060-INRAe 1397-CarMeN in Lyon to study extracellular vesicles in metabolic disorders, founding and directing the European School for the Study of Extracellular Vesicles (ESSEV, @EV_School_ESSEV).

Publications

Publications

Image document

Comparison of antioxidant efficiencies in oil‐in‐water emulsion using extracellular vesicles from olive co‐products or liposomes as antioxidants carriers

Bruno Baréa , Nathalie Barouh , Amal Fenaghra , Pascal Colosetti , Jérôme Lecomte et al.
Journal of the American Oil Chemists' Society, 2025, 102 (2), pp.323-337. ⟨10.1002/aocs.12887⟩
Article dans une revue hal-04677987 v1
Image document

Extracellular vesicles from olive wastewater and pomace by‐products: Isolation, characterization of their lipid and phenolic profiles, and evaluation of their radical scavenging activity

Nathalie Barouh , Amal Fenaghra , Pascal Colosetti , Jérôme Lecomte , Bruno Baréa et al.
European Journal of Lipid Science and Technology, 2024, 126 (10), pp.2400019. ⟨10.1002/ejlt.202400019⟩
Article dans une revue hal-04701823 v1
Image document

Use of Nanovesicles from Orange Juice to Reverse Diet-Induced Gut Modifications in Diet-Induced Obese Mice

Emmanuelle Berger , Pascal Colosetti , Audrey Jalabert , Emmanuelle Meugnier , Oscar Wiklander et al.
Molecular Therapy - Methods and Clinical Development, 2020, 18, pp.880-892. ⟨10.1016/j.omtm.2020.08.009⟩
Article dans une revue hal-02952992 v1
Image document

Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells

Justine Leclerc , David Garandeau , Charlotte Pandiani , Céline Gaudel , Karine Bille et al.
Oncogene, 2019, 38 (8), pp.1282-1295. ⟨10.1038/s41388-018-0500-0⟩
Article dans une revue inserm-02529819 v1

The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim.

Lazaro E Aira , Elodie Villa , Pascal Colosetti , Parvati Gamas , Laurie Signetti et al.
Oncogene, 2018, 37 (16), pp.2122 - 2136. ⟨10.1038/s41388-017-0112-0⟩
Article dans une revue inserm-01814383 v1
Image document

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

Mohamed Amine Hamouda , Arnaud Jacquel , Guillaume Robert , Alexandre Puissant , Valentine Richez et al.
Journal of Experimental Medicine, 2016, [Epub ahead of print]. ⟨10.1084/jem.20150983⟩
Article dans une revue inserm-01353362 v1

Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux

Sandy Giuliano , Yann Cormerais , Maeva Dufies , Renaud Grépin , Pascal Colosetti et al.
Autophagy, 2015, 11 (10), pp.1891-1904. ⟨10.1080/15548627.2015.1085742⟩
Article dans une revue hal-02108861 v1

Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors.

Sébastien Grosso , Alexandre Puissant , Maeva Dufies , Pascal Colosetti , Arnaud Jacquel et al.
Molecular Cancer Therapeutics, 2009, 8 (7), pp.1924-33. ⟨10.1158/1535-7163.MCT-09-0168⟩
Article dans une revue hal-00419091 v1

The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice.

Sandrine Marchetti , Parvati Gamas , Nathalie Belhacène , Sebastien Grosso , Ludivine A Pradelli et al.
EMBO Journal, 2009, 28 (16), pp.2449-60. ⟨10.1038/emboj.2009.183⟩
Article dans une revue hal-00419195 v1
Image document

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

Issam Ben Sahra , Kathiane Laurent , Agnès Loubat , Sophie Giorgetti Peraldi , Pascal Colosetti et al.
Oncogene, 2008, 27 (25), pp.3576-86. ⟨10.1038/sj.onc.1211024⟩
Article dans une revue inserm-00277135 v1

Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

Frederic Luciano , Arnaud Jacquel , Pascal Colosetti , Magali Herrant , Sebastien Cagnol et al.
Oncogene, 2003, 22 (43), pp.6785-93. ⟨10.1038/sj.onc.1206792⟩
Article dans une revue hal-00323924 v1

The type 3 inositol 1,4,5-trisphosphate receptor is concentrated at the tight junction level in polarized MDCK cells

P. Colosetti , R.E. Tunwell , C. Cruttwell , J.P. Arsanto , J.P. Mauger et al.
Journal of Cell Science, 2003, 116, pp.2791-2803
Article dans une revue hal-00306513 v1